




RealRate

PHARMACEUTICAL 2022

Coeptis Therapeutics Inc
Rank 435 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Coeptis Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Coeptis Therapeutics Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Coeptis Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 119% points.

The company's Economic Capital Ratio, given in the ranking table, is 118%, being 157% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	2,180
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,765
Liabilities, Non-Current	1,650
Other Assets	4,572
Other Compr. Net Income	0
Other Expenses	190
Other Liabilities	0
Other Net Income	784
Other Revenues	75
Property and Equipment	14
Research and Development	0
Selling, General and Administrative Expense	14,118

Output Variable	Value in 1000 USD
Assets	6,766
Liabilities	4,415
Expenses	14,308
Revenues	75
Stockholders Equity	2,351
Net Income	-13,449
Comprehensive Net Income	-13,449
BaseVar	13,174
ECR before Limited Liability	-149%
Economic Capital Ratio	118%